A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2

By sjmartinez • February 27, 2024

Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2. Ann Intern Med. 2024 Feb 27. doi: 10.7326/M23-2593. Epub ahead of print. PMID: 38408357.

Tags: Infectious Diseases, Publications

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]

Advanced HIV Disease at First Diagnosis in South Brazil Extended Beyond Traditionally Targeted Populations: A 10-Year Hospital-Based Study (2015-2024)

Hernandez CJ, Fonseca PM, Noal A, Zywica M, Cambou MC, Varella IRDS, Santos BR, de Melo MG, Nielsen-Saines K. Advanced HIV Disease at First Diagnosis[...]

Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI in stewardship operations

Dora AV, Benjamin LN, Graber CJ, Branch-Elliman W. Does AI know how to choose wisely? Do not trust and definitely verify when using generative AI[...]